

Aflibercept (Eylea[®], Eylea HD[®], Pavblu[™]) Injection

When requesting an aflibercept product, the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indications

Eylea and Pavblu are indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Retinopathy of prematurity (ROP)

Eylea HD is indicated for the treatment of patients with:

- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)

Approved Off-Label Compendial Uses

Eylea and Pavblu

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, sickle cell neovascularization, choroidal neovascular conditions)

Coverage Guidelines

Eylea and Pavblu

For all approved indications the individual must meet the following criteria for approval:

- Administered by or under the supervision of an ophthalmologist.

Eylea HD

For all approved indications the individual must meet the following criteria for approval:

- Administered by or under the supervision of an ophthalmologist.

Approval duration (Eylea, Eylea HD, and Pavblu): 12 months

Dosing Recommendations

Eylea and Pavblu

Neovascular (Wet) Age-Related Macular Degeneration (AMD)

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg via intravitreal injection once every 8 weeks.

Macular Edema Following Retinal Vein Occlusion (RVO)

The recommended dose is 2 mg administered by intravitreal injection once every 4 weeks.

Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 5 injections followed by 2 mg via intravitreal injection once every 8 weeks.

Retinopathy of Prematurity (ROP)

The recommended dose is 0.4 mg administered by intravitreal injection. The treatment interval between doses injected into the same eye should be at least 10 days.

Eylea HD

Neovascular (Wet) Age-related Macular Degeneration (AMD)

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks.

Diabetic Macular Edema

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks.

Diabetic Retinopathy

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 12 weeks.

Macular Edema Following Retinal Vein Occlusion (RVO)

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 to 5 doses, followed by 8 mg via intravitreal injection once every 8 weeks.

References

1. Eylea® injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; October 2024.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.
6. Eylea® HD intravitreal injection [prescribing information]. Tarrytown, NY: Regeneron; November 2025..
7. Pavblu™ intravitreal injection [prescribing information]. Thousand Oaks, CA: Amgen; August 2024.